Results 21 to 30 of about 104,102 (217)

Facilitating Expedited Drug Approval—the Past, Present, and Future of Clinical Trials for Pediatric Rheumatic Disease

Arthritis Care &Research, EarlyView.
Pamela F. Weiss, Hermine I. Brunner
wiley   +1 more source

Caregiver Reports on the Needs and Experiences of Children Impacted by Parental Incarceration: Results From an Australian Survey

Australian Journal of Social Issues, EarlyView.
ABSTRACT Children experiencing parental imprisonment are known to be among the most overlooked in our community. They often experience multiple and compounding disadvantages, with long‐term consequences, but receive no specialised assistance. Knowledge about these children and their families is lacking in Australia and is required to inform policy ...
Catherine Flynn, Lana Battaglia, Lorana Bartels, Susan Dennison, Susy Harrigan, Lee Huggins, Sofia Grage‐Moore   +6 more
wiley   +1 more source

How Are Australian Local Governments Responding to the Homelessness Crisis? Findings From a National Study

Australian Journal of Social Issues, EarlyView.
ABSTRACT Australian local governments are facing intensifying pressures to respond to worsening visible homelessness. This paper presents one of the first national studies on how local governments are responding to these pressures, and the first since the onset of the post‐pandemic housing crisis.
Andrew Clarke, Joelle Moore, Fatemeh Aminpour, Katya Eagles   +3 more
wiley   +1 more source

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study

Annals of Neurology, EarlyView.
In multiple sclerosis (MS), anti‐CD20 therapies have been associated with increased infection risk, but whether this risk differs between rituximab and ocrelizumab is not known. Using a nationwide cohort, we studied infection risk and relapse outcomes among 16,872 treatment episodes with rituximab, ocrelizumab, or other disease‐modifying therapies ...
Thomas Frisell, Sebastian Hedberg, Fredrik Piehl   +2 more
wiley   +1 more source

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration

Arthritis &Rheumatology, EarlyView.
Objective To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...
Zubeyir Salis, Denis Mongin, Denis Choquette, Louis Coupal, Catalin Codreanu, Florenzo Iannone, Roberto Caporali, Tore K. Kvien, Sella Provan, Ruth Fritsch‐Stork, Dan Nordström, Nina Trokovic, Karel Pavelka, Jakub Závada, Ana Rodrigues, Ziga Rotar, Prodromos Sidiropoulos, Irini Flouri, Céline Lamacchia, Michele Iudici, Delphine Courvoisier, Kim Lauper, Axel Finckh   +22 more
wiley   +1 more source

Non‐melanoma skin cancer risk with Janus kinase inhibitors compared to interleukin‐6 receptor inhibitors in rheumatoid arthritis: results from a national cohort study

Arthritis &Rheumatology, Accepted Article.
Background Non‐melanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with Janus kinase inhibitors (JAKi) compared to interleukin‐6 receptor inhibitors (IL‐6Ri). Method This study used data from the British Society for Rheumatology Rheumatoid Arthritis Register (BSRBR‐RA) linked
Zixing Tian, Lianne Kearsley‐Fleet, Sizheng Steven Zhao, James Galloway, Mark Lunt, Kath Watson, Narges Azadbakht, BSRBR‐RA Contributors Group, Kimme L Hyrich   +8 more
wiley   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source